This study is currently not recruiting participants.

OPZ003; Phase 1b/2 Multicenter Open-label Study of Oprozomib and Dexamethasone in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma

Study on the Safety and Tolerability of Oprozomib with Dexamethasone

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is deteremine the maximum tolerated dose(MTD) of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide and to evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide.

Detailed description of study

The purpose of this study is to establish the maximum tolerated dose (MTD) of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide and to evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: multiple myeloma
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the safety and tolerability of an investigational medication when used with dexamethasone. The purpose is to find the maximum dose that can be tolerated without causing severe side effects. This dose is called the maximum tolerated dose (MTD). The study looks at how this combination works with lenalidomide or oral cyclophosphamide, which are other treatments used in certain conditions.

Participants in the study will receive either lenalidomide or oral cyclophosphamide along with the investigational medication and dexamethasone. The study will monitor participants closely to see how their bodies react to these combinations and to ensure that the treatments are safe.

  • Who can participate: Eligibility criteria were not provided in the source information. Basic criteria typically include age range and specific medical conditions targeted by the study.
  • Study details: Participants will receive treatment that includes an investigational medication combined with dexamethasone and either lenalidomide or oral cyclophosphamide. The study will observe how participants respond to these treatments.
Updated on 19 Feb 2024. Study ID: 1401235239

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team